Steatohepatitis/Metabolic Liver Disease News

PHILADELPHIA — In this exclusive video perspective from the American College of Gastroenterology Annual Meeting, Sean Rudnick, MD, from Wake Forest University, discusses hepatic porphyria and the need to raise awareness about the disease.

SAN FRANCISCO — Beyond finding a “cure” to nonalcoholic fatty liver disease, one expert at The Liver Meeting 2018 called on physicians and governments alike to fight the root cause of the disease.

SAN FRANCISCO — Results from a phase 2b trial showed that Aramchol— a stearoyl coenzyme desaturase A inhibitor — significantly reduced liver fat and improved histology with excellent safety and tolerability in patients with nonalcoholic fatty liver disease, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — VK2809, a thyroid receptor beta agonist, showed an impact on nearly all treated patients as measured by magnetic resonance imaging-proton density fat fraction, according to late breaking data presented at The Liver Meeting 2018.

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Karl E. Anderson, MD, from the University of Texas Medical Branch, discusses positive phase 1/2 results for givosiran, an investigational RNAi therapeutic for patients with acute intermittent porphyria.

SAN FRANCISCO — Although previously reported effective at a 3 mg dose, NGM282 showed similar efficacy in treating nonalcoholic steatohepatitis at 1 mg, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Liver grafts with high macrosteatosis correlated with a higher posttransplant mortality in patients with obesity compared with patients with normal BMI, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Over 10 years, from 2005 to 2014, the number of patients with a diagnosis of nonalcoholic fatty liver disease increased by 260% and costs jumping 86%, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Patients with non-alcoholic fatty liver disease carried a 91% higher risk for malignancy and the risk for cancer with obesity is “driven by NAFLD,” according to a presentation at The Liver Meeting 2018.

SAN FRANCISCO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage from The Liver Meeting 2018.